The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Aclaris Therapeutics, Inc.’s ACRS share price has surged by 10.08%, which has investors questioning if this is right time to sell.

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Brensocatib is Currently Under Priority Review with the U.S. Food and Drug Administration— BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ...

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA ...

Patient endorsed history of chronic sinusitis with nasal polyps and underwent sinus surgery twice in the past. He denied allergies to NSAIDs or aspirin, and he was referred to ENT and was found to ...

North West Deputy North West Regional Chief Pharmacist urges people to order required repeat prescriptions ahead of the May bank holiday ...

North West Deputy North West Regional Chief Pharmacist urges people to order required repeat prescriptions ahead of the May ...